Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: Requirement for E4 ORF3

Journal of Virology

Volumn 73, Issue 10, 1999, Pages 8308-8319

  Lusky, M ^a   Grave, L ^a   Dieterle A ^a   Dreyer, D ^a   Christ, M ^a   Ziller, C ^a   Furstenberger, P ^a   Kintz, J ^a   Ali Hadji, D ^a   Pavirani, A ^a   Mehtali, M ^a  

^a TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; GENE DELETION; GENE EXPRESSION REGULATION; GENE THERAPY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS GENOME;

EID: 0032823287     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.10.8308-8319.1999     Document Type: Article

References (65)

1. Armentano, D., J. Zabner, C. Sacks, C. C. Sookdeo, M. P. Smith, J. A. St. George, S. C. Wadsworth, A. E. Smith, and R. J. Gregory. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408-2416.
2. Barr, D., J. Tubb, D. Fergusson, A. Scaria, A. Lieber, C. Wilson, J. Perkins, and M. A. Kay. 1995. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2:151-155.
3. Bellon, G., L. Michel-Calemard, D. Thouvenot, V. Jagneaux, F. Poitevin, C. Malcus, N. Accart, M. P. Layani, M. Aymard, H. Bernon, J. Bienvenu, M. Courtney, G. Döring, B. Gilly, R. Gilly, D. Lamy, H. Levrey, Y. Morel, C. Paulin, F. Perraud, L. Rodillon, C. Sené, S. So, F. Touraine-Monlin, C. Schatz, and A. Pavirani. 1997. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum. Gene. Ther. 8:15-25.
4. Berkner, K. L. 1988. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6:616-629.
5. Boivin, D., M. R. Morrison, R. C. Marcellus, E. Querido, and P. E. Branton. 1999. Analysis of synthesis, stability, phosphorylation, and interacting polypeptides of the 34-kilodalton product of open reading frame 6 of the early region 4 protein of human adenovirus type 5. J. Virol. 73:1245-1253.
6. Boshart, M., F. Weber, G. Jahn, K. Dorsch-Hasler, B. Fleckenstein, and W. Schaffner. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521-530.
7. Bowles, N. E., and Q. Wang. 1997. Prospect for adenovirus-mediated gene therapy of inherited diseases of the myocardium. Cardiovasc. Res. 35:422-430.
8. Bridge, E., and G. Ketner. 1989. Redundant control of adenovirus late gene expression by early region 4. J. Virol. 63:631-638.
9. Bridge, E., S. Medghalchi, S. Ubol, M. Leesong, and G. Ketner. 1993. Adenovirus early region 4 and viral DNA synthesis. Virology 193:794-801.
10. Brough, D. E., C. Hsu, V. A. Kulesa, G. M. Lee, L. J. Cantolupo, A. Lizonova, and I. Kovesdi. 1997. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J. Virol. 71:9206-9213.
11. Carvalho, T., J.-S. Seeler, K. Ohman, P. Jordan, U. Pettersson, G. Akusjarvi, M. Carmo-Fonseca, and A. Dejean. 1995. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131:45-56.
12. Challberg, S. S., and G. Ketner. 1981. Deletion mutants of adenovirus 2: isolation and initial characterization of virus carrying mutations near the right end of the viral genome. Virology 114:196-209.
13. Chartier, C., E. Degryse, M. Gantzer, A. Dieterlé, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 79:4805-4810.
14. Christ, M., M. Lusky, F. Stoeckel, D. Dreyer, A, Dieterlé, A. I. Michou, A. Pavirani, and M. Mehtali. 1997. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. 57:19-25.
15. Christ, M., et al. Submitted for publication.
16. Chroboczek, J., F. Bieber, and B. Jacrot. 1992. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186:280-285.
17. Clayman, G. L., A. K. El-Naggar, S. M. Lippman, Y. C Henderson, M. Frederick, J. A. Merritt, L. A. Zumstein, T. M. Timmons, T. J. Liu, L. Ginsberg, J. A. Roth, W. K. Hong, P. Bruso, and H. Goepfert. 1998. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16:2221-2232.
18. Connelly, S., T. A. G. Smith, G. Dhir, J. M. Gardner, M. G. Mehaffey, K. S. Zaret, A. McLelland, and M. Kaleko. 1995. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther. 6:185-193.
19. Crystal, R. G., N. G. McElvaney, M. A. Rosenfeld, C.-S. Chu, A. Mastrangeli, J. G. Hay, S. L. Brody, H. A. Jafe, N. T. Eissa, and C. Daniel. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:42-51.
20. Czerkinsky, C. C., L.-A. Nilsson, H. Nygren, O. Ouchterlony, and A. Tarkowski. 1983. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 65:109-121.
21. Dai, Y., E. M. Schwarz, D. Gu, W. W. Zhang, N. Sarvetnick, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
22. Dedieu, J.-F., E. Vigne, C. Torrent, C. Jullien, I. Mahfouz, J. M. Caillaud. N. Aubailly, C. Orisini, J. M. Guillaume, P. Opolon, P. Delaère, M. Perricaudet, and P. Yeh. 1997. Long-term gene delivery into the livers of immuno-competent mice with E1/E4-defective adenoviruses. J. Viral. 71:4626-4637.
23. Doucas, V., A. M. Ishov, A. Roma, H. Juguilon, M. D. Weitzman, R. M. Evans, and G. G. Maul. 1996. Adenovirus replication is coupled with dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207.
24. Dyck, I. A, G. G. Maul, W. Miller, J. D. Chen, Jr., A. Kakizuka, and R. M. Evans. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333-343.
25. Engelhardt, J. F., L. Litzky, and J. M. Wilson. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses in E2a. Hum. Gene Ther. 5:1217-1229.
26. Fang, B., H. Wang, G. Gordon, D. A. Bellinger, M. S. Read, K. M. Brinkhous, S. L. C. Woo, and R. C. Eisensmith. 1996. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 3:217-222.
27. Gahéry-Ségard, H., V. Molinier-Frenkel, C. Le Boulaire, P. Saulnier, P. Opolon, R. Lengagne, E. Gautier, A. Le Cesne, L. Zitvogel, A. Venet, C. Schatz, M. Courtney, T. Le Chevalier, T. Tursz, J. G. Guillet, and F. Farace. 1997. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune response to transgene and viral products. J. Clin. Investig. 100:2218-2226.
28. Gao, G. P., Y. Yang, and J. M. Wilson. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70:8934-8943.
29. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
30. Graham, F. L., and L. Prevec. 1992. Adenovirus based expression vectors and recombinant vaccines, p. 363-390. In R. W. Ellis (ed.), Vaccines: new approaches to immunological problems. Butterworth-Heinemann, Newton, Mass.
31. Grave, L., et al. Submitted for publication.
32. Guérin, E., M.-G. Ludwig, P. Basset, and P. Angiard. 1997. Stromelysin-3 induction and interstitial collagenase repression by retinoic acid. J. Biol. Chem. 272:11088-11095.
33. Hoang, M.-M., and P. Hearing. 1989. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J. Virol. 63:2605-2615.
34. Huang, M.-M., and P. Hearing. 1989. The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor E2F, through a direct complex. Genes Dev. 3:1699-1710.
35. Kass-Eissler, A., E. Falck-Pedersen, D. H. Elfenbein, M. Alvira, P. M. Buttrick, and L. A. Leinwand. 1994. The impact of development stage, route of administration, and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1:395-402.
36. Kleinberger, T., and T. Shenk. 1993. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription. J. Virol. 67:7556-7560.
37. Lavoie, J. N., M. Nguyen, R. C. Marcellus, P. E. Branton, and G. C. Shore. 1998. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway which is not inhibited by zVAD-fmk. J. Cell Biol. 140:637-645.
38. Leppard, K. N. 1997. E4 gene function in adenovirus, adenovirus-vector and adeno-associated virus infections. J. Gen. Virol. 78:2131-2138.
39. Li, Q., M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet, and S. L. Woo. 1993. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4:403-409.
40. Lusky, M., M. Christ, K. Rittner, A. Dieterlé, D. Dreyer, B. Mourot, H. Schultz, F. Stoeckel, A. Pavirani, and M. Mehtali. 1998. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72:2022-2032.
41. Lusty, M. Unpublished data.
42. Marcellus, R. C., J. N. Lavole, D. Boivin, G. C. Shore, G. Ketner, and P. E. Branton. 1998. The early region 4 orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis. J. Virol. 72:7144-7153.
43. Michou, A. I., L. Santoro, M. Christ, V. Julliard, A. Pavirani, and M. Mehtali. 1997. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 4:473-482.
44. Mittereder, N., K. L. March, and B. C. Trapnell. 1996. Evaluation of the concentration and bioactivity of adenovectors for gene therapy. J. Virol. 70:7498-7509.
45. Morral, N., W. O'Neal, H. Zhou, C. Längston, and A. Beaudet. 1997. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther. 8:1275-1286.
46. Müller, U., T. Klelnberger, and T. Shenk. 1992. Adenovirus E4orf4 reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1. J. Virol. 66:5867-5878.
47. Nabel, E. G., V. J. Pompili, G. E. Plautz, and G. J. Nabel. 1994. Gene transfer and vascular disease. Cardiovasc. Res. 35:422-430.
48. Nordqvist, K., K. Öhman, and G. Akusjärvi. 1994. Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs. Mol. Cell. Biol. 14:437-445.
49. Ohman, K., K, Nordqvist, and G. Akusjärvi. 1993. Two adenovirus proteins with redundant activities in virus growth facilitate tripartite leader mRNA accumulation. Virology 194:50-58.
50. O'Neal, W. K., H. Zhou, N. Morral, E. Aguilar-Cordova, J. Pestaner, C. Längston, B. Mull, Y. Wang, A. L. Beaudet, and B. Lee. 1998. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors express-ing alphal-antitrypsin after systemic delivery. Hum. Gene Ther. 9:1587-1598.
51. Otake, K., D. L. Ennist, K. Harrod, and B. C. Trapnell. 1998. Non-specific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum. Gene Ther. 10:2207-2222.
52. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
53. Scaria, A., J. A. St. George, C. Jiang, J. M. Kaplan, S. C. Wadsworth, and R. J. Gregory. 1998. Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium. J. Virol. 72:7302-7309.
54. Schuler, M., C. Roschlitz, J. A. Horowitz, J. Schlegel, A. P. Perruchoud, F. Kommoss, C. T. Bolliger, H. U. Kauczor, P. Dalquen, M. A. Fritz, S. Swanson, R. Hermann, and C. Huber. 1998. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. 14:2075-2082.
55. Shenk, T. 1996. Adenoviridae: the viruses and their replication, p. 2111-2148. In B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Virology. Raven Press, Philadelphia, Pa.
56. Shtrichman, R., and T. Kleinberger. 1998. Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells. J. Virol. 72:2975-2982.
57. Smith, T. A. G., M. G. Mehafey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McLelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:392-402.
58. Trapnell, B. C. 1993. Adenoviral vectors for gene transfer. Adv. Drug Delivery Rev. 12:185-199.
59. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
60. Virtanen, A., P. Gillardi, A. Naslund, J. M. Lemoullec, U. Pettersson, and M. Perricaudet. 1984. mRNAs from human adenovirus 2 early region 4. J. Virol. 51:822-831.
61. Wang, Q., G. Greenburg, D. Bunch, D. Farson, and M. H. Finer. 1997. Persistent transgene expression in mouse liver following in vivo gene transfer with a △E1/△E4 adenovirus vector. Gene Ther. 4:393-400.
62. Yang, Y., K. U. Jooss, Q. Su, H. C. J. Ertl, and J. M. Wilson. 1996. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-inffected hepatocytes in vivo. Gene Ther. 3:137-144.
63. Yao, S. N., A. Farjo, B. J. Roessler, B. L. Davidson, and K. Kurachi. 1996. Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the trans-gene in liver. Vir. Immunol. 9:141-153.
64. Yen, P., J. F. Dedieu, C. Orsini, E. Vigne, P. Denefie, and M. Perricaudet. 1996. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70:559-565.
65. Zabner, J., B. W. Ramsey, D. P. Meeker, M. L. Aitken, R. P. Balfour, R. L. Gibson, I. Launspach. R A. Moscicki, S. M. Richards, T. A. Standaert, J. Williams-Warren, S. C. Wadsworth, A. E. Smith, and M. J. Welsh. 1996. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Investig. 97:1504-1511.